Liver enzyme function in people with cardiogenic shock on heart pumps
Part of Heart & circulation clinical trials.
This study tests whether your liver’s drug-processing enzymes (CYP) work normally during cardiogenic shock when you are on a heart pump like ECMO or Impella®. The goal is to help doctors choose the right medicines for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cardiogenic shock (heart too weak to pump enough blood) with or without a temporary heart pump like ECMO or Impella®.
- You are 18 years or older.
- You understand French and can give consent (a family member or legal representative can provide consent if needed).
- You do NOT have severe lung failure requiring a special lung bypass (VV-ECMO).
- You do NOT have severe kidney disease (GFR under 30) or severe liver disease (Child-Pugh B or C).
- You are not allergic to any of the study drugs: caffeine, midazolam, omeprazole, losartan, or dextromethorphan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial studies whether a special synchronized “heart support” treatment is safer and works better for people in cardiogenic shock. It aims to improve blood flow to organs when the heart can’t pump enough.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
This trial studies whether doctors can safely reduce heart and blood-pressure support sooner in people with severe heart failure “shock.” It may help avoid side effects of strong medicines/devices while keeping the body’s organs well supported.
This trial tests a treatment plan for people having a severe heart attack that causes cardiogenic shock, where the heart can't pump enough blood. The study uses a special heart pump to support patients during an emergency procedure to open blocked arteries.
Hear when a new ECMO trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.